Login / Signup

Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes.

Silva A ArslanianTamara HannonPhilip ZeitlerLily C ChaoClaudia Boucher-BerryMargarita Barrientos-PérezElise BismuthSergio DibJang Ik ChoDavid Coxnull null
Published in: The New England journal of medicine (2022)
Treatment with dulaglutide at a once-weekly dose of 0.75 mg or 1.5 mg was superior to placebo in improving glycemic control through 26 weeks among youths with type 2 diabetes who were being treated with or without metformin or basal insulin, without an effect on BMI. (Funded by Eli Lilly; AWARD-PEDS ClinicalTrials.gov number, NCT02963766.).
Keyphrases
  • glycemic control
  • type diabetes
  • body mass index
  • blood glucose
  • clinical trial
  • randomized controlled trial
  • metabolic syndrome
  • weight loss
  • adipose tissue
  • insulin resistance
  • skeletal muscle
  • placebo controlled